EUVIMEDEUVIMED entdecken
Crossref

NfL as a biomarker in ATTRv amyloidosis: potential and limitations

Massimo Russo, M De Luca, L Gentile, F D'Arma, A Pugliese, V Macaione, F Polito, L Licitri, A Cafarchio, M H Aguennouz, C Rodolico, A Mazzeo

Neurological Sciences · 2025-07 · 46 (7) · 3263-3269

DOI: 10.1007/s10072-025-08110-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurological Sciences, online erschienen am 19.03.2025. Verfasst von Massimo Russo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria N°1, Policlinico "G. Martino", Messina, Italy. russom@…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Neurofilament Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hereditary transthyretin amyloidosis (ATTRv) presents unique challenges in diagnosis and monitoring due to its phenotypic and genetic heterogeneity. This study evaluates the utility of serum neurofilaments light chains (NfL) as a reliable biomarker of disease activity in patients carrying different pathogenic TTR variants. Twenty-eight ATTRv patients carrying the following mutations (p.Phe84Leu, p.Glu109Gln, p.Thr69Ala, p.Val50Met) as well as 8 carriers and 27 healthy control subjects underwent extensive examination, including serum NfL measurement, neuropathy impairment score for the lower limb (NIS-LL), compound autonomic dysfunction test (CADT), and polyneuropathy disability (PND) scores, at T0, T6 and T12. The study not only confirms the previously established correlation between serum NfL concentrations and disease severity scales but also extends these observations to the mutations reported here. Furthermore, the research highlights the potential of serum NfLs as discriminators between presymptomatic carriers and symptomatic patients, emphasizing their utility in predicting disease onset and facilitating timely intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialNeurofilament ProteinsHumansMaleBiomarkersMiddle AgedFemaleAdultMutationAgedPrealbuminSeverity of Illness Index

Stichwörter der Autor:innen

TTR Amyloidosis, Neurofilaments, Polyneuropathy, p.Glu109Gln, p.Phe84Leu, p.Thr…

Substanzen

Biomarkersneurofilament protein LNeurofilament ProteinsPrealbumin

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria N°1, Policlinico "G. Martino", Messina, Italy. russom@unime.it.
  • Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria N°1, Policlinico "G. Martino", Messina, Italy.
  • Department of Medicine and Health Sciences "Vincenzo Tibero" DIMES, University of Molise, Campobasso, 86100, Italy.

Zitieren

APA

Russo, M., De Luca, M., Gentile, L., D'Arma, F., Pugliese, A., Macaione, V., Polito, F., Licitri, L., Cafarchio, A., Aguennouz, M. H., Rodolico, C., & Mazzeo, A. (2025). NfL as a biomarker in ATTRv amyloidosis: potential and limitations. Neurological Sciences, 46(7), 3263-3269. https://doi.org/10.1007/s10072-025-08110-0

Vancouver

Russo M, De Luca M, Gentile L, D'Arma F, Pugliese A, Macaione V, et al. NfL as a biomarker in ATTRv amyloidosis: potential and limitations. Neurological Sciences. 2025;46(7):3263-3269. doi:10.1007/s10072-025-08110-0

BibTeX
@article{Russo2025,
  author = {Russo, Massimo and De Luca, M and Gentile, L and D'Arma, F and Pugliese, A and Macaione, V and Polito, F and Licitri, L and Cafarchio, A and Aguennouz, M H and Rodolico, C and Mazzeo, A},
  title = {NfL as a biomarker in ATTRv amyloidosis: potential and limitations},
  journal = {Neurological Sciences},
  year = {2025},
  volume = {46},
  number = {7},
  pages = {3263--3269},
  doi = {10.1007/s10072-025-08110-0}
}
Kostenlos starten →